This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fuchs, P C Articles by Thornsberry, C Search for Related Content PubMed PubMed Citation Articles by Fuchs, P C Articles by Thornsberry, C

Next Article 

Antimicrob Agents Chemother. 1985 May; 27(5): 679-682

Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin.

P C Fuchs, R N Jones, A L Barry and C Thornsberry

ABSTRACT

The in vitro activity of BMY-28142, a new cephalosporin, was tested by a broth microdilution system and compared with those of cefotaxime, ceftazidime, cefoperazone, moxalactam, and HR 810 against 747 bacterial isolates, one-third of which were resistant to one or more third-generation cephalosporins. BMY-28142 was the most active drug tested against 326 Enterobacteriaceae with an MIC for 90% of the organisms tested (MIC90) of 1.0 micrograms/ml. Against these Enterobacteriaceae the relative activities were: BMY-28142 greater than HR 810 greater than moxalactam and ceftazidime greater than cefotaxime greater than cefoperazone. For cefotaxime- and cefoperazone-resistant strains, the MIC90 of BMY-28142 was 4.0 micrograms/ml (compared with 0.13 micrograms/ml for susceptible strains). BMY-28142, with an MIC90 of 8.0 micrograms/ml for Pseudomonas aeruginosa, was about half as active as ceftazidime. The relative activities against P. aeruginosa were: ceftazidime greater than BMY-28142 greater than HR 810 greater than cefoperazone greater than moxalactam and cefotaxime. The MIC90 of BMY-28142 against staphylococci was 2.0 micrograms/ml, which was fourfold less active than HR 810, slightly less active than cefotaxime and cefoperazone, and fourfold more active than ceftazidime and moxalactam. BMY-28142 was very active against beta-lactamase-positive and -negative Haemophilus influenzae (MIC90, 0.06 micrograms/ml), Neisseria gonorrhoeae (MIC90, 0.015 micrograms/ml),aand nonenterococcal streptococci. Its activity against Streptococcus faecalis was poor (MIC90, 64 micrograms/ml). BMY-28142 was stable against the several beta-lactamases tested but exhibited little beta-lactamase inhibitory effect.

---

Antimicrob Agents Chemother. 1985 May; 27(5): 679-682

This article has been cited by other articles:

• Tam, V. H., McKinnon, P. S., Akins, R. L., Drusano, G. L., Rybak, M. J. (2003). Pharmacokinetics and Pharmacodynamics of Cefepime in Patients with Various Degrees of Renal Function. Antimicrob. Agents Chemother. 47: 1853-1861 [Abstract] [Full Text]  
• Lister, P. D., Sanders, W. E. Jr., Sanders, C. C. (1998). Cefepime-Aztreonam: a Unique Double beta -Lactam Combination for Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 42: 1610-1619 [Abstract] [Full Text]  
• Barza, M., Lynch, E., Baum, J. L. (1993). Pharmacokinetics of Newer Cephalosporins After Subconjunctival and Intravitreal Injection in Rabbits. Arch Ophthalmol 111: 121-125 [Abstract]